Can a shorter radiation course for prostate cancer be just as safe?

NCT ID NCT05820633

Terminated Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shorter treatment causes similar side effects and maintains quality of life. 500 participants are planned, but the trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy (ultra-hypofractionated pelvic IMRT with HDR brachytherapy boost)
What this could lead to: If successful, this could show that a shorter course of radiation is just as safe and effective as the standard longer course for prostate cancer patients.
What could go wrong: This trial is currently suspended, so results may be delayed or not happen. It is a non-inferiority study, meaning it aims to prove the new approach is not worse than the standard, not necessarily better. Side effects from radiation remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NODE; PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NODE; PROSTATE PROSTATE CANCER RADIOTHERAPY SIDE EFFECT

Contacts and locations

Locations

BC Cancer Sindi Ahluwalia centre for the Southern Interior

Kelowna, British Columbia, V1Y 5L3, Canada
CHU de Québec - Université Laval

Québec, G1R 2J6, Canada
CISSS de Laval, Hôpital de la Cité-de-la-Santé

Laval, Quebec, H7M 3L9, Canada
CISSS de l'Outaouais, Hôpital de Gatineau

Gatineau, Quebec, J8P 7H2, Canada
CISSS de la Montérégie-Centre, Hôpital Charles-Le Moyne

Longueuil, Quebec, J4V 2H1, Canada
CIUSSS de l'Est-de-l'Île-de-Montréal, Hôpital Maisonneuve-Rosemont

Montreal East, Quebec, H1T 2M4, Canada
CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)

Sherbrooke, Quebec, Canada
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal, Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
Carlo Fidani Peel Regional Cancer Centre

Mississauga, Ontario, L5M 2N1, Canada
Cedars Cancer Centre, McGill University Health Centre (MUHC)

Montreal, Quebec, H4A 3J1, Canada
Lakeridge Health Oshawa Cancer centre

Oshawa, Ontario, L1G 2B9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.